Neupogen and Zarxio are indicated to: Decrease the incidence of infection‚ as manifested by FN‚ in patients with nonmyeloid malignancies.
Zarxio (filgrastim- sndz), Nivestym (filgrastim-aafi), and Releuko (filgrastim-ayow) are biosimilars to Neupogen and approved for most
Filgrastim. (Neupogen), filgrastim-aafi (Nivestym), filgrastim-sndz (Zarxio). [NCCN Web site]. 2024. Available at:
filgrastim (Granix- not interchangeable), and filgrastim-sndz (Zarxio-biosimilar to Neupogen and not with vials vs pre-filled syringes or
Neupogen, Nivestym, Releuko, and Zarxio are indicated to: Decrease the incidence of infection‚ as manifested by FN‚ in patients with
of NIVESTYM vs Neupogen (filgrastim) in healthy subjects3. NIVESTYM. (n=128) Zarxio (filgrastim-sndz) is a registered trademark of Novartis AG.
Nivestym (filgrastim-aafi), Releuko (filgrastim-ayow), and Zarxio (filgrastim-sndz) are approved as biosimilars to Neupogen (filgrastim).
The first biosimilar to be approved in the United States, in 2024, was filgrastim-sndz (Zarxio), a biosimilar to filgrastim (Neupogen), which is
Neupogen, Nivestym, and Zarxio are indicated to: Decrease the incidence of infection‚ as manifested by FN‚ in patients with nonmyeloid
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are